Close Menu
Varta24 Business
    What's Hot

    Merit Over Mandate: Tata Trusts Clarifies Eligibility for Leadership

    April 4, 2026

    Beyond the Paycheck: Tackling the “Misfit” Crisis in the Modern Workplace

    April 4, 2026

    Delhi HC Halts Tax Recovery on Partner Bonuses; Directs CBDT to Clarify Rules

    April 4, 2026
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Varta24 BusinessVarta24 Business
    Subscribe
    • Home
    • Top News
    • Companies
    • Finance
    • Insurance
    • Markets
    • Technology
    • World News
    Varta24 Business
    Home»Markets»Tata Motors vs M&M vs Maruti: March 2026 Sales Analysis
    Markets

    Tata Motors vs M&M vs Maruti: March 2026 Sales Analysis

    Aruna KaimBy Aruna KaimApril 2, 2026No Comments3 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    The March 2026 quarter (Q4FY26) revealed a diverging landscape for India’s auto giants. While domestic demand for SUVs and EVs surged, traditional small car segments faced headwinds from geopolitical uncertainties and rising input costs.

    The Leaderboard: Volume Growth (y-o-y).

    Tata Motors emerged as the clear winner in terms of growth percentage, followed closely by Mahindra & Mahindra’s SUV-heavy portfolio.

    Company % Sales Change (y-o-y) Total Units Sold (Q4FY26)
    Tata Motors (PV) +37% 201,368
    Mahindra & Mahindra +21% 301,455
    Maruti Suzuki +11.8% 676,209
    Hyundai Motor India +8.7% 208,275

    1. Tata Motors: The EV Powerhouse

    Tata Motors Passenger Vehicles took the lead by leveraging a massive 69% y-o-y jump in EV sales (27,000 units).

    • Drivers: High demand for Nexon and Punch EVs, alongside the newly launched petrol variants of Harrier and Safari.

    • Investor Focus: While domestic sales are booming, markets are eyeing the March quarter results for Jaguar Land Rover (JLR) in the UK, which is recovering from a recent cyber incident.

    2. Mahindra & Mahindra: SUV Dominance

    M&M continues to ride the “premiumization” wave, with its SUV division growing by 23.3%.

    • Key Models: The new XUV7XO (launched Jan 2026) and electric models like the BE 6 and XEV 9E are the primary growth drivers.

    • Scale: Total auto sales crossed the 3-lakh unit mark for the quarter.

    3. Maruti Suzuki & Hyundai: Export Lifelines

    Both leaders saw a slowdown or stagnation in specific domestic segments, finding relief in international markets.

    • Maruti Suzuki: Despite total volume growth, small car sales (Alto, WagonR) fell 4%. Consumers in the middle-income bracket appear cautious due to Middle East tensions. However, a 61.2% surge in exports saved the quarter.

    • Hyundai: Achieved its highest-ever domestic quarterly sales (1.66 lakh units), but relied on a 9.4% growth in exports to maintain momentum.


    Cost Pressures and Margins

    The “Iran-USA/Israel war” has sent shockwaves through the supply chain:

    • Raw Materials: Aluminium prices rose 20% ($3,200/tonne) and steel rose 10% y-o-y.

    • Response: Maruti and Hyundai have announced 2% price hikes effective April 2026 to protect margins, which have already seen contraction (Maruti’s margin shrank to 11% in Q3).

    Valuation Watch: Who is the Best Buy?

    For investors, Tata Motors currently offers the most “reasonable” entry point based on Price-to-Earnings (P/E) ratios, provided the UK operations stabilize.

    • Tata Motors PV: 18.6 P/E (Consolidated)

    • Hyundai Motor India: 23.9 P/E

    • Mahindra & Mahindra: 24.5 P/E

    • Maruti Suzuki India: 26.7 P/E

    Note: As of April 2, 2026, the market remains volatile. Investors are balancing the strong domestic festival-led momentum against the “consumer uncertainty” created by global conflicts and rising fuel costs.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleNew Delhi Slashes Petrochemical Import Duties to Shield Industries from Iran War Shock
    Next Article US Tariff Fears Trigger Bloodbath in Indian Pharma: Nifty Pharma Index Drops 3%
    Aruna Kaim

    Related Posts

    The 21,700 Line in the Sand: Nifty’s Critical Survival Test on Dalal Street

    April 4, 2026

    The Gatekeepers of Quality: 3 Stocks Riding India’s $11 Billion Testing Boom

    April 4, 2026

    Gold as a Global Lifeline: Central Banks Navigate War and the Dollar

    April 4, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    10 Trends From Year 2020 That Predict Business Apps Popularity

    January 20, 2021

    Shipping Lines Continue to Increase Fees, Firms Face More Difficulties

    January 15, 2021

    Qatar Airways Helps Bring Tens of Thousands of Seafarers

    January 15, 2021

    Subscribe to Updates

    Get the latest sports news from SportsSite about soccer, football and tennis.

    Advertisement
    Demo

    Your source for the serious news. This demo is crafted specifically to exhibit the use of the theme as a news site. Visit our main page for more demos.

    We're social. Connect with us:

    Facebook X (Twitter) Instagram Pinterest YouTube
    Top Insights

    Top UK Stocks to Watch: Capita Shares Rise as it Unveils

    January 15, 2021
    8.5

    Digital Euro Might Suck Away 8% of Banks’ Deposits

    January 12, 2021

    Oil Gains on OPEC Outlook That U.S. Growth Will Slow

    January 11, 2021
    Contact Us

    Varta24 Business

    India International Centre

    40, Max Mueller Marg

    Lodhi Estate, New Delhi-110003

    Email.varta24live@gmail.com

    © 2026 Varta24 Media, Designed by Social Fox.
    • Home
    • Markets
    • Stocks
    • Funds
    • Buy Now

    Type above and press Enter to search. Press Esc to cancel.